Developer docs
API playgroundTry for free, no card

Search company profiles

上海润诺生物科技有限公司

Full company profile

uuid003zkun

Namestring
上海润诺生物科技有限公司
Legal namestring
BioDuro LLC
Websiteurl
bioduro.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

BioDuro (上海润诺生物科技有限公司), operating as BioDuro LLC and historically known as BioDuro-Sundia following the ~2020 merger of BioDuro and Sundia, is a global Contract Research, Development, and Manufacturing Organization (CRDMO) headquartered in Irvine, California, with primary discovery operations in Shanghai, China, and 8 global campuses worldwide. Founded in 1996 by Dr. Masood Tayebi and owned by Advent International, the company employs more than 2,000 scientists and serves approximately 1,500 active customers across biotechnology, pharmaceutical, and research institutions. Services span early-stage drug discovery through commercial manufacturing: chemistry (medicinal, peptide, parallel, computational, analytical, scale-up), biology (assay development, oncology models including PDX/CDX/humanized, pharmacology), DMPK, drug substance (process R&D, kilo/pilot API), and drug product (preformulation, formulation, ASD via HME/SDD, oral-solid manufacturing at the Irvine facility with >3 billion doses annual capacity).

The company's technology platform combines proprietary and differentiated capabilities across multiple high-value modalities, including a ChemPass-trained fragment library for FBDD with SPR-driven hit identification, a DNA-encoded peptide library with 108-channel automated synthesis enabling 10-mer+ macrocycles, a PROTAC platform with 1,000+ molecules synthesized to gram scale, an integrated ADC discovery platform, a Solution Engine for amorphous solid dispersion, and MASH/NAFLD mouse models with 12–16-week readout. The Integrated Drug Discovery (IDD) platform co-locates synthetic chemistry, biology, DMPK, and pharmacology with same-day compound handoff and automated screening cascades, marketed as compressing discovery-to-IND timelines from typical 5–7 years to 2–3 years.

BioDuro generates revenue under professional services contracts on fee-for-service (FFS) and full-time-equivalent (FTE) bases, with no publicly disclosed pricing. The go-to-market is direct enterprise field sales supplemented by inside sales and dedicated project management, supported by content marketing, on-demand webinars, virtual lab tours, and active participation in major industry conferences (EFMC, CPHI, ELRIG, Boulder Peptide). Strategic alliances extend the platform: CTI Biotechnology adds GLP toxicology and bioanalytical services, the CENRA API Solutions/CCSB joint venture adds commercial API manufacturing, and partnerships with Intangia and Atombeat integrate AI-driven target intelligence and peptide discovery. The customer base includes global biotech companies (oncology, rare disease, metabolic), mid-size and large pharmaceutical companies, and virtual or early-stage biotechs lacking in-house infrastructure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, drug discovery services, pharmaceutical development, API manufacturing, preclinical CRO
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code4 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Contract Drug Research and Manufacturing (CRDMO)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research, Development and Manufacturing Services
TypeProfessional Services
Description

BioDuro generates revenue by providing fully integrated drug discovery services (Chemistry, Biology, DMPK), drug substance manufacturing (API, RSMs, intermediates), and drug product development and manufacturing (oral solid dosages, clinical trial material) on a contract services basis. Services are offered as standalone FFS (fee-for-service) or integrated FTE (full-time equivalent) engagements. Projects span from early discovery through IND filing and commercial manufacturing.

bioduro.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Integrated Drug Discovery (IDD)
Description

A platform combining chemistry, biology, DMPK, and pharmacology services to accelerate the path from target identification to preclinical candidate selection.

bioduro.com
+5 more records
Core offering1 text field

上海润诺生物科技有限公司 (BioDuro) is a global CRDMO providing fully integrated drug discovery, development, and manufacturing services. The company offers chemistry, biology, DMPK, pharmacology, and oncology research services alongside drug substance (API) and drug product (oral solid dose) manufacturing capabilities. Services span from early discovery through IND filing and commercial manufacturing for small and large molecule drug candidates, delivered as standalone FFS or integrated FTE engagements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Discovery-to-IND timelines reduced from 5-7 years to 2-3 years through integrated execution
+4 more records
Product overview1 text field

BioDuro is a fully integrated CRDMO (Contract Research, Development, and Manufacturing Organization) offering end-to-end drug discovery, development, and manufacturing services. The company provides a comprehensive suite of services organized into Discovery (Chemistry, DMPK, Biology, Oncology, Pharmacology), Drug Substance (Process R&D, Scale Up Synthesis, Manufacturing), and Drug Product (Preformulation, Formulation Development, Manufacturing) divisions. These services are supported by specialized technology platforms including Integrated Drug Discovery (IDD), Antibody-Drug Conjugate, Peptide, PROTAC, DNA-Encoded Library (DEL), Solution Engine, MASH/NASH Mouse Models, Compound Management, and IND Enabling platforms. With 2,000+ scientists across 8 global campuses serving 1,500+ active customers, BioDuro operates as a one-stop shop to accelerate innovations from early discovery through commercialization.

Product and service15 records
1Chemistry Services
CategoryDrug Discovery Services
Description

Comprehensive chemistry capabilities for drug discovery and development including Peptide Chemistry, Medicinal Chemistry, Parallel Synthesis, Computational Chemistry, Synthetic Chemistry, Analytical Chemistry, and Scale Up Chemistry, serving biotech and pharmaceutical clients globally.

2DMPK Services
CategoryDrug Discovery Services
Description

Integrated Drug Metabolism and Pharmacokinetics services including In Vivo PK and TK, In Vitro ADME, Bioanalytical Service, Toxicity studies in rodents, dogs and monkeys, and Large Molecule Development and Bioanalysis for drug discovery programs.

3Discovery Biology Services
CategoryDrug Discovery Services
Description

Cutting-edge biology technologies supporting discovery, preclinical and translational assays including Assay Development, Biochemical Assays, Cellular Assays, Ligand Binding Assays, Protein Science, Surface Plasmon Resonance (SPR), and Biologics.

4Oncology Services
CategoryPreclinical Research Services
Description

Combining classic and cutting-edge in vitro and in vivo research to support drug discovery for cancer treatment, including PDX, CDX, Orthotopic Models, Syngeneic Models, Humanized Mouse Models, CAR-T and CAR-NK Mouse Models, ELISA Assays, and In Vitro Assays.

5Pharmacology Services
CategoryPreclinical Research Services
Description

Comprehensive pharmacology studies including Immunology & Inflammation, Metabolic, MASH Mouse Models, Respiratory, Neuroscience, and Safety Pharmacology to elucidate pharmacodynamics and mechanism of action.

6Drug Substance Services
CategoryDrug Substance Manufacturing
Description

Process R&D, Scale Up Synthesis, and Drug Substance Manufacturing including Flow Chemistry, Sugar Chemistry, Peptide Chemistry, Preparative Purification, Process Safety Assessment, and Kilo/Pilot Scale API production.

7Drug Product Services
CategoryDrug Product Manufacturing
Description

Preformulation, Formulation Development, and Drug Product Manufacturing with capabilities including Hot Melt Extrusion (HME), Spray Dried Dispersion (SDD), Amorphous Solid Dispersion, Bioavailability Enhancement, and Modified Release.

8Integrated Drug Discovery (IDD) Platform
CategoryDrug Discovery Platform
Description

Fully integrated platform combining chemistry, biology, and DMPK services to accelerate discovery from target identification to preclinical candidate selection under one roof with dedicated project management and same-day compound registration and distribution.

9Antibody-Drug Conjugate (ADC) Platform
CategoryDrug Discovery Platform
Description

Specialized platform for antibody-drug conjugate discovery and development combining chemistry, biology, and DMPK expertise for targeted therapy development.

10Peptide Platform
CategoryDrug Discovery Platform
Description

Comprehensive peptide chemistry platform for drug discovery including synthetic peptide synthesis, optimization, and large-scale manufacturing, delivering over 10,000 library targets with capabilities for linear, cyclic, natural and unnatural amino acid incorporation.

11PROTAC Platform
CategoryDrug Discovery Platform
Description

Targeted protein degradation platform for PROTAC (PROteolysis Targeting Chimeras) drug discovery including chemical synthesis and in vitro biological evaluation, with over 1,000 PROTAC molecules synthesized and scaled up to gram quantities.

12DNA-Encoded Library (DEL) Platform
CategoryDrug Discovery Platform
Description

DNA-encoded library technology for high-throughput screening and hit identification in drug discovery, featuring 108-channel automated solid-phase peptide synthesis producing oligopeptide building blocks with ~90% crude purity and enabling 10-mer+ macrocyclic peptide libraries.

13Solution Engine Platform
CategoryDrug Product Platform
Description

Advanced amorphous solid dispersion (ASD) technologies for solubility and bioavailability enhancement of poorly soluble compounds, including Hot Melt Extrusion (HME), Spray Dried Dispersion (SDD), and Amorphous Solid Dispersion with 4-6 weeks in-vivo/in-vitro data turnaround.

14Compound Management Platform
CategoryDrug Discovery Platform
Description

Integrated compound management services for efficient handling and tracking of chemical libraries during drug discovery, enabling same-day synthesis-to-biology handoff for accelerated design-synthesize-test cycles.

15IND Enabling Services
CategoryRegulatory Services
Description

Comprehensive IND filing support services including API process development, pre-formulation studies, and integrated project management for regulatory submissions across FDA, NMPA, and other global markets.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-28
Description

Broad collaboration spanning discovery through CMC for GV-100, a novel oral selective HDAC6 inhibitor for ADPKD. BioDuro provided API process development and production, pre-formulation studies, and integrated project management for the IND-enabling program, supporting successful advancement into Phase I clinical development in Australia. Gilva is a Taiwan-based biopharmaceutical company focused on innovative small molecule therapies for rare diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Strategic partnership combining BioDuro's integrated discovery (chemistry, biology, DMPK, CMC) and CTI's GLP toxicology studies and bioanalytical services. Together they offer a one-stop discovery-to-IND submission platform for global biotech and pharma clients. CTI has assisted in 143 IND approvals including 19 FDA approvals. Founded in Kunshan, Suzhou in 2011 as an investment by Centre Testing International Group (Stock Code: 300012).

3CENRA API Solutions / CCSB
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Joint venture partnership adding commercial API manufacturing capacity. The partnership offers flexible, coordinated approach with unified quality systems, regulatory readiness, and support across small molecules, peptides, and fermentation products. Combined capabilities help programs scale from development to commercial production.

bioduro.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

AI-driven target intelligence partnership connecting Intangia's platform for identifying, prioritizing, and validating novel target and indication opportunities with BioDuro's integrated discovery execution capabilities. Enables workflow from 'what should we test?' to 'how should we test it?' and 'what data is needed to make a decision?' Intangia was incubated by F-Prime Capital.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

AI-driven peptide drug discovery partnership. Atombeat is both a valued client and strategic partner of BioDuro in developing an AI-powered platform for accelerated peptide drug discovery. Founded by leading computational and medicinal chemists.

Strategic tierNotableTypeOthers
Description

BioDuro's Irvine facility has partnered with FDA to showcase and provide training for FDA Consumer Safety Officers and FDA Medical Product Analysts on pharmaceutical new and novel technology, demonstrating regulatory trust and collaboration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China/US CRO and CDMO offering discovery chemistry, biology, pharmacology and manufacturing services. Comparable integrated model targeting biotech and mid-pharma with overlapping capability set.

TypeBroad incumbent
Description

Leading global CDMO with biologics, small molecules and cell & gene therapy manufacturing. Comparable on the drug substance and drug product manufacturing side of BioDuro's CRDMO offering.

TypeDirect peer
Description

Fully integrated drug R&D and CDMO with labs in China, UK and US providing chemistry, biology, DMPK, API and drug product services. Highly comparable integrated CRDMO model with similar cross-border operating footprint.

TypeBroad incumbent
Description

Largest global CRO with broad clinical and laboratory services including R&D solutions, bioanalytical and central labs. Competes at the upper end of the integrated services market that BioDuro targets.

TypeDirect peer
Description

China-headquartered fully integrated CRDMO offering discovery, CMC and commercial manufacturing across small and large molecules. Closest direct competitor to BioDuro in scale, scope and customer base, particularly for US biotech seeking integrated discovery-to-IND programs.

TypeEmerging player
Description

Mid-size CDMO with integrated API, drug product and discovery services. Smaller in scale than BioDuro but comparable scope in small-molecule CMC and contract manufacturing.

TypeBroad incumbent
Description

Global CDMO with deep formulation and drug product capabilities including softgel, oral solids and biologics. Competes directly with BioDuro's drug product and bioavailability enhancement (Solution Engine) services.

8Asymchem Laboratories
TypeDirect peer
Description

China-based API CDMO with growing integrated discovery/CMC capabilities serving global pharma and biotech. Comparable small-molecule manufacturing and contract research services with similar geographic and operational profile.

TypeBroad incumbent
Description

Large incumbent CRO/CDMO offering discovery, safety assessment, manufacturing and clinical support across North America, Europe and Asia. Overlaps with BioDuro across preclinical/CMC and competes for enterprise pharma outsourcing contracts.

TypeBroad incumbent
Description

Major clinical and bioanalytical lab services provider with broad CRO capabilities. Overlaps with BioDuro in central lab, bioanalytical and drug development support.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles23 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

上海润诺生物科技有限公司

Contract Drug Research and Manufacturing (CRDMO)bioduro.com

What 上海润诺生物科技有限公司 does

BioDuro (上海润诺生物科技有限公司), operating as BioDuro LLC and historically known as BioDuro-Sundia following the ~2020 merger of BioDuro and Sundia, is a global Contract Research, Development, and Manufacturing Organization (CRDMO) headquartered in Irvine, California, with primary discovery operations in Shanghai, China, and 8 global campuses worldwide. Founded in 1996 by Dr. Masood Tayebi and owned by Advent International, the company employs more than 2,000 scientists and serves approximately 1,500 active customers across biotechnology, pharmaceutical, and research institutions. Services span early-stage drug discovery through commercial manufacturing: chemistry (medicinal, peptide, parallel, computational, analytical, scale-up), biology (assay development, oncology models including PDX/CDX/humanized, pharmacology), DMPK, drug substance (process R&D, kilo/pilot API), and drug product (preformulation, formulation, ASD via HME/SDD, oral-solid manufacturing at the Irvine facility with >3 billion doses annual capacity).

The company's technology platform combines proprietary and differentiated capabilities across multiple high-value modalities, including a ChemPass-trained fragment library for FBDD with SPR-driven hit identification, a DNA-encoded peptide library with 108-channel automated synthesis enabling 10-mer+ macrocycles, a PROTAC platform with 1,000+ molecules synthesized to gram scale, an integrated ADC discovery platform, a Solution Engine for amorphous solid dispersion, and MASH/NAFLD mouse models with 12–16-week readout. The Integrated Drug Discovery (IDD) platform co-locates synthetic chemistry, biology, DMPK, and pharmacology with same-day compound handoff and automated screening cascades, marketed as compressing discovery-to-IND timelines from typical 5–7 years to 2–3 years.

BioDuro generates revenue under professional services contracts on fee-for-service (FFS) and full-time-equivalent (FTE) bases, with no publicly disclosed pricing. The go-to-market is direct enterprise field sales supplemented by inside sales and dedicated project management, supported by content marketing, on-demand webinars, virtual lab tours, and active participation in major industry conferences (EFMC, CPHI, ELRIG, Boulder Peptide). Strategic alliances extend the platform: CTI Biotechnology adds GLP toxicology and bioanalytical services, the CENRA API Solutions/CCSB joint venture adds commercial API manufacturing, and partnerships with Intangia and Atombeat integrate AI-driven target intelligence and peptide discovery. The customer base includes global biotech companies (oncology, rare disease, metabolic), mid-size and large pharmaceutical companies, and virtual or early-stage biotechs lacking in-house infrastructure.

上海润诺生物科技有限公司 firmographics

Firmographics
Name
上海润诺生物科技有限公司
Legal name
BioDuro LLC
Website
https://bioduro.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

上海润诺生物科技有限公司 industry classification

Industry
Product category
Contract Drug Research and Manufacturing (CRDMO)
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Contract research services
  • Drug discovery services
  • Pharmaceutical development
  • API manufacturing
  • Preclinical CRO

Where 上海润诺生物科技有限公司 is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices3 records

Markets served

上海润诺生物科技有限公司 business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research, Development and Manufacturing Services: BioDuro generates revenue by providing fully integrated drug discovery services (Chemistry, Biology, DMPK), drug substance manufacturing (API, RSMs, intermediates), and drug product development and manufacturing (oral solid dosages, clinical trial material) on a contract services basis. Services are offered as standalone FFS (fee-for-service) or integrated FTE (full-time equivalent) engagements. Projects span from early discovery through IND filing and commercial manufacturing.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

上海润诺生物科技有限公司 product offering

Product offering

Core offering

上海润诺生物科技有限公司 (BioDuro) is a global CRDMO providing fully integrated drug discovery, development, and manufacturing services. The company offers chemistry, biology, DMPK, pharmacology, and oncology research services alongside drug substance (API) and drug product (oral solid dose) manufacturing capabilities. Services span from early discovery through IND filing and commercial manufacturing for small and large molecule drug candidates, delivered as standalone FFS or integrated FTE engagements.

Product overview

BioDuro is a fully integrated CRDMO (Contract Research, Development, and Manufacturing Organization) offering end-to-end drug discovery, development, and manufacturing services. The company provides a comprehensive suite of services organized into Discovery (Chemistry, DMPK, Biology, Oncology, Pharmacology), Drug Substance (Process R&D, Scale Up Synthesis, Manufacturing), and Drug Product (Preformulation, Formulation Development, Manufacturing) divisions. These services are supported by specialized technology platforms including Integrated Drug Discovery (IDD), Antibody-Drug Conjugate, Peptide, PROTAC, DNA-Encoded Library (DEL), Solution Engine, MASH/NASH Mouse Models, Compound Management, and IND Enabling platforms. With 2,000+ scientists across 8 global campuses serving 1,500+ active customers, BioDuro operates as a one-stop shop to accelerate innovations from early discovery through commercialization.

Differentiator

Problem solved

Functional benefit

Brands

  • Integrated Drug Discovery (IDD): A platform combining chemistry, biology, DMPK, and pharmacology services to accelerate the path from target identification to preclinical candidate selection.
  • Solution Engine
  • DNA-Encoded Library (DEL)
  • PROTAC Platform
  • NASH/MASH Mouse Models
  • Compound Management

Products and services

  • Chemistry Services Comprehensive chemistry capabilities for drug discovery and development including Peptide Chemistry, Medicinal Chemistry, Parallel Synthesis, Computational Chemistry, Synthetic Chemistry, Analytical Chemistry, and Scale Up Chemistry, serving biotech and pharmaceutical clients globally.
  • DMPK Services Integrated Drug Metabolism and Pharmacokinetics services including In Vivo PK and TK, In Vitro ADME, Bioanalytical Service, Toxicity studies in rodents, dogs and monkeys, and Large Molecule Development and Bioanalysis for drug discovery programs.
  • Discovery Biology Services Cutting-edge biology technologies supporting discovery, preclinical and translational assays including Assay Development, Biochemical Assays, Cellular Assays, Ligand Binding Assays, Protein Science, Surface Plasmon Resonance (SPR), and Biologics.
  • Oncology Services Combining classic and cutting-edge in vitro and in vivo research to support drug discovery for cancer treatment, including PDX, CDX, Orthotopic Models, Syngeneic Models, Humanized Mouse Models, CAR-T and CAR-NK Mouse Models, ELISA Assays, and In Vitro Assays.
  • Pharmacology Services Comprehensive pharmacology studies including Immunology & Inflammation, Metabolic, MASH Mouse Models, Respiratory, Neuroscience, and Safety Pharmacology to elucidate pharmacodynamics and mechanism of action.
  • Drug Substance Services Process R&D, Scale Up Synthesis, and Drug Substance Manufacturing including Flow Chemistry, Sugar Chemistry, Peptide Chemistry, Preparative Purification, Process Safety Assessment, and Kilo/Pilot Scale API production.
  • Drug Product Services Preformulation, Formulation Development, and Drug Product Manufacturing with capabilities including Hot Melt Extrusion (HME), Spray Dried Dispersion (SDD), Amorphous Solid Dispersion, Bioavailability Enhancement, and Modified Release.
  • Integrated Drug Discovery (IDD) Platform Fully integrated platform combining chemistry, biology, and DMPK services to accelerate discovery from target identification to preclinical candidate selection under one roof with dedicated project management and same-day compound registration and distribution.
  • Antibody-Drug Conjugate (ADC) Platform Specialized platform for antibody-drug conjugate discovery and development combining chemistry, biology, and DMPK expertise for targeted therapy development.
  • Peptide Platform Comprehensive peptide chemistry platform for drug discovery including synthetic peptide synthesis, optimization, and large-scale manufacturing, delivering over 10,000 library targets with capabilities for linear, cyclic, natural and unnatural amino acid incorporation.
  • PROTAC Platform Targeted protein degradation platform for PROTAC (PROteolysis Targeting Chimeras) drug discovery including chemical synthesis and in vitro biological evaluation, with over 1,000 PROTAC molecules synthesized and scaled up to gram quantities.
  • DNA-Encoded Library (DEL) Platform DNA-encoded library technology for high-throughput screening and hit identification in drug discovery, featuring 108-channel automated solid-phase peptide synthesis producing oligopeptide building blocks with ~90% crude purity and enabling 10-mer+ macrocyclic peptide libraries.
  • Solution Engine Platform Advanced amorphous solid dispersion (ASD) technologies for solubility and bioavailability enhancement of poorly soluble compounds, including Hot Melt Extrusion (HME), Spray Dried Dispersion (SDD), and Amorphous Solid Dispersion with 4-6 weeks in-vivo/in-vitro data turnaround.
  • Compound Management Platform Integrated compound management services for efficient handling and tracking of chemical libraries during drug discovery, enabling same-day synthesis-to-biology handoff for accelerated design-synthesize-test cycles.
  • IND Enabling Services Comprehensive IND filing support services including API process development, pre-formulation studies, and integrated project management for regulatory submissions across FDA, NMPA, and other global markets.

Quantifiable outcome

  • Discovery-to-IND timelines reduced from 5-7 years to 2-3 years through integrated execution
  • +4 more outcomes

Companies that use 上海润诺生物科技有限公司

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

上海润诺生物科技有限公司 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

上海润诺生物科技有限公司 partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, major, strategic and notable.

  • Gilva TherapeuticscoreStrategic or Co-development Partner · 28 May 2026Broad collaboration spanning discovery through CMC for GV-100, a novel oral selective HDAC6 inhibitor for ADPKD. BioDuro provided API process development and production, pre-formulation studies, and integrated project management for the IND-enabling program, supporting successful advancement into Phase I clinical development in Australia. Gilva is a Taiwan-based biopharmaceutical company focused on innovative small molecule therapies for rare diseases.
  • CTI Biotechnology (Suzhou) Co., Ltd.coreStrategic or Co-development Partner · 28 April 2026Strategic partnership combining BioDuro's integrated discovery (chemistry, biology, DMPK, CMC) and CTI's GLP toxicology studies and bioanalytical services. Together they offer a one-stop discovery-to-IND submission platform for global biotech and pharma clients. CTI has assisted in 143 IND approvals including 19 FDA approvals. Founded in Kunshan, Suzhou in 2011 as an investment by Centre Testing International Group (Stock Code: 300012).
  • CENRA API Solutions / CCSBmajorStrategic or Co-development PartnerJoint venture partnership adding commercial API manufacturing capacity. The partnership offers flexible, coordinated approach with unified quality systems, regulatory readiness, and support across small molecules, peptides, and fermentation products. Combined capabilities help programs scale from development to commercial production.
  • IntangiastrategicStrategic or Co-development PartnerAI-driven target intelligence partnership connecting Intangia's platform for identifying, prioritizing, and validating novel target and indication opportunities with BioDuro's integrated discovery execution capabilities. Enables workflow from 'what should we test?' to 'how should we test it?' and 'what data is needed to make a decision?' Intangia was incubated by F-Prime Capital.
  • AtombeatstrategicStrategic or Co-development PartnerAI-driven peptide drug discovery partnership. Atombeat is both a valued client and strategic partner of BioDuro in developing an AI-powered platform for accelerated peptide drug discovery. Founded by leading computational and medicinal chemists.
  • FDA (US Food and Drug Administration)notableOthersBioDuro's Irvine facility has partnered with FDA to showcase and provide training for FDA Consumer Safety Officers and FDA Medical Product Analysts on pharmaceutical new and novel technology, demonstrating regulatory trust and collaboration.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

上海润诺生物科技有限公司 competitors and assessment

Company assessment

Direct peers

  • ChemPartner: China/US CRO and CDMO offering discovery chemistry, biology, pharmacology and manufacturing services. Comparable integrated model targeting biotech and mid-pharma with overlapping capability set.
  • Pharmaron: Fully integrated drug R&D and CDMO with labs in China, UK and US providing chemistry, biology, DMPK, API and drug product services. Highly comparable integrated CRDMO model with similar cross-border operating footprint.
  • WuXi AppTec: China-headquartered fully integrated CRDMO offering discovery, CMC and commercial manufacturing across small and large molecules. Closest direct competitor to BioDuro in scale, scope and customer base, particularly for US biotech seeking integrated discovery-to-IND programs.
  • Asymchem Laboratories: China-based API CDMO with growing integrated discovery/CMC capabilities serving global pharma and biotech. Comparable small-molecule manufacturing and contract research services with similar geographic and operational profile.

Broad incumbents

  • Lonza Group: Leading global CDMO with biologics, small molecules and cell & gene therapy manufacturing. Comparable on the drug substance and drug product manufacturing side of BioDuro's CRDMO offering.
  • IQVIA: Largest global CRO with broad clinical and laboratory services including R&D solutions, bioanalytical and central labs. Competes at the upper end of the integrated services market that BioDuro targets.
  • Catalent: Global CDMO with deep formulation and drug product capabilities including softgel, oral solids and biologics. Competes directly with BioDuro's drug product and bioavailability enhancement (Solution Engine) services.
  • Charles River Laboratories: Large incumbent CRO/CDMO offering discovery, safety assessment, manufacturing and clinical support across North America, Europe and Asia. Overlaps with BioDuro across preclinical/CMC and competes for enterprise pharma outsourcing contracts.
  • Labcorp (Labcorp Drug Development / Fortrea): Major clinical and bioanalytical lab services provider with broad CRO capabilities. Overlaps with BioDuro in central lab, bioanalytical and drug development support.

Emerging players

  • Curia (formerly AMRI): Mid-size CDMO with integrated API, drug product and discovery services. Smaller in scale than BioDuro but comparable scope in small-molecule CMC and contract manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

上海润诺生物科技有限公司 social profiles

Digital presence

上海润诺生物科技有限公司 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

上海润诺生物科技有限公司 leadership team

Management profile

Number of profiles

Profiles23 records

上海润诺生物科技有限公司 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

上海润诺生物科技有限公司 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 上海润诺生物科技有限公司

What does 上海润诺生物科技有限公司 do?

上海润诺生物科技有限公司 (BioDuro) is a global CRDMO providing fully integrated drug discovery, development, and manufacturing services. The company offers chemistry, biology, DMPK, pharmacology, and oncology research services alongside drug substance (API) and drug product (oral solid dose) manufacturing capabilities. Services span from early discovery through IND filing and commercial manufacturing for small and large molecule drug candidates, delivered as standalone FFS or integrated FTE engagements.

Is 上海润诺生物科技有限公司 a public or private company?

上海润诺生物科技有限公司 is a private company. It is classified as private equity controlled and is currently operating.

When was 上海润诺生物科技有限公司 founded?

上海润诺生物科技有限公司 was founded in 1996. It employs 51 to 100 people.

Where is 上海润诺生物科技有限公司 based?

上海润诺生物科技有限公司 is headquartered in Irvine, United States, in the North America region.

How does 上海润诺生物科技有限公司 make money?

One revenue line is on record: contract Research, Development and Manufacturing Services.

Who are 上海润诺生物科技有限公司's main competitors?

Direct peers on record are ChemPartner, Pharmaron, WuXi AppTec and Asymchem Laboratories. Broad incumbents are Lonza Group, IQVIA, Catalent, Charles River Laboratories and Labcorp (Labcorp Drug Development / Fortrea). Curia (formerly AMRI) is listed as an emerging player.

Does 上海润诺生物科技有限公司 have an API?

No public API is recorded for 上海润诺生物科技有限公司.

What industry is 上海润诺生物科技有限公司 in?

上海润诺生物科技有限公司's product category is Contract Drug Research and Manufacturing (CRDMO). Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals